한글목차

다사티닙 의약품 시장은 2025년에 16억 4,610만 달러로 평가되었고, 2032년에는 24억 7,510만 달러에 이를 것으로 예측되며, 2025년부터 2032년에 걸쳐 CAGR 6%로 성장할 전망입니다.

다사티닙은 특정 유형의 암 치료에 혁신을 가져온 잠재적인 티로신 키나제 억제제입니다. 처음에는 만성 골수성 백혈병(CML)과 필라델피아 염색체 양성 급성 림프구성 백혈병(Ph+ ALL)을 대상으로 한 표적 치료제로 개발된 다사티닙은 BCR-ABL 단백질을 특이적으로 표적화하고 억제하여 암 세포의 성장과 증식을 억제합니다. 뛰어난 효능을 보여, 다사티닙은 이러한 악성 종양 환자의 치료 결과와 생존율을 크게 개선했습니다. 또한 다사티닙은 SRC 가족 키나제 등 다른 티로신 키나제에 대한 억제 효과를 나타내며, 다양한 종양에 대한 적용 가능성을 넓히고 있습니다. 다사티닙은 유망한 치료 옵션이지만 부작용이 동반되므로 주의 깊은 모니터링과 관리가 필요합니다. 현재 진행 중인 연구와 임상 시험은 다사티닙의 복합 요법 가능성을 탐구하며, 암 치료 전략의 추가적인 발전을 위한 길을 열고 있습니다.

시장 역학 :

암의 유병률 증가, 우수한 임상 결과, 승인된 적응증의 확대는 예측 기간 동안 세계의 다사티닙 의약품 시장의 성장을 촉진할 것으로 예상됩니다. 또한 표적 치료제의 개발도 예측 기간 동안 세계의 다사티닙 의약품 시장의 성장을 촉진할 것으로 예상됩니다. 신흥 시장 진출, 복합 요법, 소아 적응증, 제네릭 제품 개발은 예측 기간 동안 세계의 다사티닙 의약품 시장 성장에 성장 기회를 창출할 것으로 예상됩니다.

그러나 치료 비용의 고비용, 엄격한 규제 요건, 잠재적 부작용, 내성 발달은 예측 기간 동안 다사티닙 의약품 시장 성장을 방해할 것으로 예상됩니다.

본 조사의 주요 특징

• 본 보고서에서는 세계의 다사티닙 의약품 시장을 상세하게 분석했으며, 2024년을 기준 연도으로 한 예측 기간 2025-2032년 시장 규모 및 CAGR을 제공합니다.
• 또, 다양한 부문에 걸친 잠재적인 수익 기회를 밝혀, 이 시장의 매력적인 투자 제안 매트릭스를 해설했습니다.
• 또한 시장 성장 촉진요인, 억제요인, 기회, 신제품 발매 및 승인, 시장 동향, 지역별 전망, 주요 기업이 채택하는 경쟁 전략 등에 관한 주요 고찰도 제공합니다.
• 기업 하이라이트, 제품 포트폴리오, 주요 하이라이트, 업적, 전략 등의 파라미터에 근거해, 세계의 다사티닙 의약품 시장에 있어서의 주요 기업 프로파일을 제공합니다.
• 본 보고서의 통찰에 의해 마케팅 담당자나 기업의 경영진은 장래의 제품 출시, 제품 업그레이드, 시장 확대, 마케팅 전술에 관한 정보에 근거한 의사 결정을 실시할 수 있습니다.
• 세계의 다사티닙 의약품 시장 보고서는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 참가자, 재무 분석가 등 이 업계의 다양한 이해 관계자에 대응하고 있습니다.
• 이해관계자는 세계의 다사티닙 의약품 시장 분석에 사용되는 다양한 전략 매트릭스를 통해 의사결정이 용이해집니다.

목차

제1장 조사의 목적과 전제조건

• 조사 목적
• 전제조건
• 약어

제2장 시장 전망

• 보고서 설명
  • 시장 정의와 범위
• 주요 요약
• 일관된 기회 지도(COM)

제3장 시장 역학, 규제, 동향 분석

• 시장 역학
  • 성장 촉진요인
• 암의 이환율 증가
  • 억제요인
• 제품 리콜 증가
  • 기회
• 신흥 시장 진출
• 복합 요법
• 소아 적응증
• 영향 분석
• 주요 하이라이트
• 규제 시나리오
• 제품 출시 및 승인
• PEST 분석
• PORTER 분석
• 합병과 인수 시나리오

제4장 코로나바이러스(COVID-19) 팬데믹의 영향

• COVID-19 역학
• 공급 측면 및 수요 측면 분석
• 경제에 미치는 영향

제5장 다사티닙 의약품 시장 : 유형별(2020-2032년)

• 20mg
• 50mg
• 70mg

제6장 다사티닙 의약품 시장 : 적응증별(2020-2032년)

• 만성 골수성 백혈병
• 급성 림프성 백혈병

제7장 다사티닙 의약품 시장 : 유통 채널별(2020-2032년)

• 병원 약국
• 소매 약국
• 온라인 약국

제8장 다사티닙 의약품 시장 : 지역별(2020-2032년)

• 북미
  • 미국
  • 캐나다
  • 영국
  • 독일
  • 이탈리아
  • 프랑스
  • 스페인
  • 러시아
  • 기타 유럽
• 아시아태평양
  • 중국
  • 인도
  • 일본
  • 호주
  • 한국
  • ASEAN
  • 기타 아시아태평양
  • 브라질
  • 멕시코
  • 아르헨티나
  • 기타 라틴아메리카
• 중동
  • GCC 국가
  • 이스라엘
  • 기타 중동
• 아프리카
  • 북아프리카
  • 남아프리카
  • 중앙 아프리카

제9장 경쟁 구도

• Bristol-Myers Squibb
  • MSN Labs
  • Hetero Labs
  • Alembic Pharma,
  • JINLAN Pharm-Drugs Technology Co., Ltd.,
  • Reddy's,
  • Zhejiang Hisun Pharma

제10장 섹션

• 조사 방법
• 회사 소개

영문목차

Dasatinib Drugs Market is estimated to be valued at USD 1,646.1 Mn in 2025 and is expected to reach USD 2,475.1 Mn by 2032, growing at a compound annual growth rate (CAGR) of 6% from 2025 to 2032.

Dasatinib is a potential tyrosine kinase inhibitor that has revolutionized the treatment landscape for certain types of cancer. Initially developed as a targeted therapy for chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL), dasatinib specifically targets and inhibits the BCR-ABL protein, suppressing the growth and proliferation of cancer cells. With remarkable efficacy, dasatinib has significantly improved outcomes and increased survival rates in patients with these malignancies. Moreover, dasatinib exhibits inhibitory effects on other tyrosine kinases, including SRC family kinases, broadening its potential application to various tumors. While dasatinib offers a promising therapeutic option, it is not without side effects, necessitating careful monitoring and management. Ongoing research and clinical trials are exploring the potential of dasatinib in combination therapies, paving the way for further advancements in cancer treatment strategies.

Market Dynamics:

The increasing prevalence of cancer, favorable clinical outcomes, and expansion of approved indications are anticipated to drive the growth of the global dasatinib drugs market over the forecast period. Moreover, the development of targeted therapies is also expected to boost the growth of the global dasatinib drugs market over the forecast period. Expansion into emerging markets, combination therapies, pediatric indications, and the development of generic versions are expected to create growth opportunities for the global dasatinib drugs market growth during the forecast period.

However, the high cost of treatment, stringent regulatory requirements, potential adverse effects, the development of resistance are expected to hamper the growth of the dasatinib drugs market over the forecast period.

Key features of the study:

• This report provides an in-depth analysis of the global dasatinib drugs market, and provides market size (US$ Mn) and compound annual growth rate (CAGR %) for the forecast period 2025-2032, considering 2024 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global dasatinib drugs market based on the following parameters - company highlights, product portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include Bristol-Myers Squibb Company, MSN Labs, Lupin, Dr. Reddy's Laboratories, Gilead Sciences, Inc., Hetero Labs, MANUS AKTTEVA BIOPHARMA LLP, Alembic Pharma, JINLAN Pharm-Drugs Technology Co., Ltd., and Zhejiang Hisun Pharma
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global dasatinib drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global dasatinib drugs market

Detailed Segmentation:

• Dasatinib Drugs Market, By Type:
  • 20 mg
  • 50 mg
  • 70 mg
• Dasatinib Drugs Market, By Indication:
  • Chronic Myeloid Leukemia
  • Acute Lymphoblastic Leukemia
  • Others
• Dasatinib Drugs Market, By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• Dasatinib drugs market, By Region:
  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East
  • Africa
• Company Profiles:
  • Bristol-Myers Squibb
  • MSN Labs
  • Lupin
  • Dr. Reddy's Laboratories
  • Hetero Labs
  • MANUS AKTTEVA BIOPHARMA LLP
  • Alembic Pharma
  • JINLAN Pharm-Drugs Technology Co., Ltd.
  • Reddy's Laboratories
  • Zhejiang Hisun Pharma

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snippet, By Type
  • Market Snippet, By Indication
  • Market Snippet, By Distribution channel
  • Market Snippet, By Region
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Drivers
• Increasing prevalence of cancer
  • Restraints
• Increasing product recall
  • Opportunities
• Expansion into emerging markets
• Combination therapies
• Pediatric indications
• Impact Analysis
• Key Highlights
• Regulatory Scenario
• Product launch/Approvals
• PEST Analysis
• PORTER's Analysis
• Merger and Acquisition Scenario

4. Dasatinib Drugs Market - Impact of Coronavirus (COVID-19) Pandemic

• COVID-19 Epidemiology
• Supply Side and Demand Side Analysis
• Economic Impact

5. Dasatinib Drugs Market, By Type, 2020-2032, (US$ Mn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021- 2032
  • Segment Trends
• 20 mg
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Mn)
• 50 mg
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Mn)
• 70 mg
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Mn)

6. Dasatinib Drugs Market, By Indication, 2020-2032, (US$ Mn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Chronic Myeloid Leukemia
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Mn)
• Acute Lymphoblastic Leukemia
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Mn)

7. Dasatinib Drugs Market, By Distribution Channel, 2020-2032, (US$ Mn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Hospital Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Mn)
• Retail Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Mn)
• Online Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Mn)

8. Dasatinib Drugs Market, By Region, 2020-2032, (US$ Mn)

• Introduction
  • Market Share Analysis, By Country, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, For Country 2021 -2032
  • Country Trends
• North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Type, 2020-2032, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020-2032, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (US$ Mn)
    • U.S.
    • Canada
  • Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Type, 2020-2032, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020-2032, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (US$ Mn)
    • U.K.
    • Germany
    • Italy
    • France
    • Spain
    • Russia
    • Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Type, 2020-2032, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020-2032, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (US$ Mn)
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Type, 2020-2032, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020-2032, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (US$ Mn)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
• Middle East
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Type, 2020-2032, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020-2032, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (US$ Mn)
    • GCC Countries
    • Israel
    • Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Type, 2020-2032, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020-2032, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2020-2032, (US$ Mn)
    • North Africa
    • South Africa
    • Central Africa

9. Competitive Landscape

• Bristol-Myers Squibb
  • Company Highlights
• Product Portfolio
• Key Developments
• Financial Performance
• Strategies
  • MSN Labs
• Company Highlights
• Product Portfolio
• Key Highlights
• Financial Performance
• Strategies
  • Hetero Labs
• Company Highlights
• Product Portfolio
• Key Highlights
• Financial Performance
• Strategies
  • Alembic Pharma,
• Company Highlights
• Product Portfolio
• Key Highlights
• Financial Performance
• Strategies
  • JINLAN Pharm-Drugs Technology Co., Ltd.,
• Company Highlights
• Product Portfolio
• Key Highlights
• Financial Performance
• Strategies
  • Reddy's,
• Company Highlights
• Product Portfolio
• Key Highlights
• Financial Performance
• Strategies
  • Zhejiang Hisun Pharma
• Company Highlights
• Product Portfolio
• Key Highlights
• Financial Performance
• Strategies
  • Analyst Views

10. Section

• Research Methodology
• About us